A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Category: Uncategorized

FDA to Review Eliquis (Apixaban) for DVT and PE Treatment

Stephan Moll, MD writes… On Dec 19th the FDA accepted the application by Bristol-Myers Squibb (BMS) and Pfizer for review of Eliquis (apixaban) for the treatment of DVT and PE. The press release of BMS is here. The goal date for a decision by the FDA is August 25, 2014.

January 6, 2014
Highlights of the 2013 ASH Annual Meeting

Stephan Moll, MD writes… The annual meeting of the American Society of Hematology (ASH) took place this month (Dec 6-12th, 2013) in New Orleans. The clinically relevant highlights about thrombosis and anticoagulation are summarized below.

December 31, 2013
Handout for Your Patients in Clinic – Which Anticoagulant to Use for DVT and PE

Stephan Moll, MD writes… Patients who are on warfarin for a history of DVT or PE may inquire whether a switch to one of the new oral anticoagulants is appropriate. Similarly, many physicians initiate this discussion with their patients. This is, obviously, a detailed discussion and an individualized decision with a number of factors to be considered.…

December 19, 2013
Do Compression Stockings Prevent Postthrombotic Syndrome? – “No”

Stephan Moll, MD writes… A new publication in the Lancet [ref 1] shows that elastic compression stockings after a first episode of proximal DVT do NOT prevent postthrombotic syndrome (PTS) as assessed over 2 years.

December 18, 2013
Reversing Warfarin for Urgent Surgeries – Extended FDA Approval of Kcentra

Stephan Moll, MD writes… The FDA approved today (Dec 13th, 2013) the use of the drug Kcentra® for urgent warfarin reversal in patients who need an urgent surgical procedure. This extends the indications for use of this drug – it had been approved by the FDA in April 2013 to treat major bleeding on warfarin…

December 13, 2013
Three Things We Shouldn’t Do

Stephan Moll, MD writes… The American Society of Hematology (ASH) has identified 3 things that physicians dealing with DVT, PE and anticoagulation should avoid – published today [ref 1].

December 4, 2013
LMWH and Epidural Catheters – FDA Recommendations

Stephan Moll, MD writes… The FDA published today a drug safety recommendation to decrease bleeding and paralysis risk for patients receiving epidural catheters and being treated with LMWH (detailed FDA report is here). While in many parts of the document the FDA talks specifically about enoxaparin, the communication states that “these new timing recommendations….. will be added to the…

November 6, 2013
Pulmonary Hypertension due to PE: New Drug Approved

Stephan Moll, MD writes… On Oct 8th, 2013 the FDA approved Adempas® (riociguat), a new oral drug to treat pulmonary hypertension. The drug is a guanylate cyclase stimulator that leads to arteries dilatation. It is intended for: Patients with chronic thromboembolic pulmonary hypertension (CTEPH)

October 16, 2013